IPDQF (Impedimed) Cash, Cash Equivalents, Marketable Securities : $11.21 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Impedimed Cash, Cash Equivalents, Marketable Securities?

Impedimed's quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 ($24.70 Mil) to Jun. 2024 ($16.36 Mil) but then stayed the same from Jun. 2024 ($16.36 Mil) to Dec. 2024 ($11.21 Mil).

Impedimed's annual cash, cash equivalents, marketable securities increased from Jun. 2022 ($28.62 Mil) to Jun. 2023 ($30.68 Mil) but then declined from Jun. 2023 ($30.68 Mil) to Jun. 2024 ($16.36 Mil).

Impedimed Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Impedimed's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impedimed Cash, Cash Equivalents, Marketable Securities Chart

Impedimed Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

13.57

15.05

28.62

30.68

16.36

Impedimed Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															17.68	30.68	24.70	16.36	11.21

Impedimed Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Impedimed (OTCPK:IPDQF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Impedimed Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Impedimed's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Impedimed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (OTCPK:IPDQF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

IPD:Australia

Address

50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008

Website

https://www.impedimed.com

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.